These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37522012)

  • 1. Assessment of the efficacy of 0.1% cyclosporine A cationic emulsion in the treatment of dry eye disease during COVID-19 pandemic.
    Stopyra W
    Rom J Ophthalmol; 2023; 67(2):164-168. PubMed ID: 37522012
    [No Abstract]   [Full Text] [Related]  

  • 2. One-Year Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in the Treatment of Severe Dry Eye Disease.
    Baudouin C; de la Maza MS; Amrane M; Garrigue JS; Ismail D; Figueiredo FC; Leonardi A
    Eur J Ophthalmol; 2017 Nov; 27(6):678-685. PubMed ID: 28708219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial.
    Leonardi A; Van Setten G; Amrane M; Ismail D; Garrigue JS; Figueiredo FC; Baudouin C
    Eur J Ophthalmol; 2016 Jun; 26(4):287-96. PubMed ID: 27055414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of 0.1% ciclosporin A cationic emulsion in dry eye disease: a pooled analysis of two double-masked, randomised, vehicle-controlled phase III clinical studies.
    Leonardi A; Messmer EM; Labetoulle M; Amrane M; Garrigue JS; Ismail D; Sainz-de-la-Maza M; Figueiredo FC; Baudouin C
    Br J Ophthalmol; 2019 Jan; 103(1):125-131. PubMed ID: 29545413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized study of the efficacy and safety of 0.1% cyclosporine A cationic emulsion in treatment of moderate to severe dry eye.
    Baudouin C; Figueiredo FC; Messmer EM; Ismail D; Amrane M; Garrigue JS; Bonini S; Leonardi A
    Eur J Ophthalmol; 2017 Aug; 27(5):520-530. PubMed ID: 28362054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistence of Efficacy of 0.1% Cyclosporin A Cationic Emulsion in Subjects with Severe Keratitis Due to Dry Eye Disease: A Nonrandomized, Open-label Extension of the SANSIKA Study.
    Labetoulle M; Leonardi A; Amrane M; Ismail D; Garrigue JS; Garhöfer G; de la Maza MS; Baudouin C
    Clin Ther; 2018 Nov; 40(11):1894-1906. PubMed ID: 30389343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world insights and outcomes related to ciclosporin A 0.1% cationic emulsion for the long-term treatment of dry eye disease in Germany: Country-level sub-analysis of the PERSPECTIVE study.
    Lanzl I; Deuter CME; Lorenz K; Geerling G;
    Graefes Arch Clin Exp Ophthalmol; 2024 Oct; 262(10):3261-3271. PubMed ID: 38722320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Switching from Cyclosporine A 0.05% Anionic Emulsion to Cyclosporine A 0.1% Cationic Emulsion in Patients with Dry Eye Associated with Sjögren's Syndrome.
    Kim J; Moon TK; Yoon HJ; Ji YS; Yoon KC
    J Ocul Pharmacol Ther; 2021 Oct; 37(8):472-478. PubMed ID: 34449255
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy of a new topical cationic emulsion of cyclosporine A on dry eye clinical signs in an experimental mouse model of dry eye.
    Daull P; Feraille L; Barabino S; Cimbolini N; Antonelli S; Mauro V; Garrigue JS
    Exp Eye Res; 2016 Dec; 153():159-164. PubMed ID: 27777121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease.
    Wirta DL; Torkildsen GL; Moreira HR; Lonsdale JD; Ciolino JB; Jentsch G; Beckert M; Ousler GW; Steven P; Krösser S
    Ophthalmology; 2019 Jun; 126(6):792-800. PubMed ID: 30703441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1/2 trial.
    Liew SH; Nichols KK; Klamerus KJ; Li JZ; Zhang M; Foulks GN
    Ophthalmology; 2012 Jul; 119(7):1328-35. PubMed ID: 22525048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy evaluation of 0.05% cyclosporine A and 0.1% tacrolimus eye drops in the treatment of severe dry eye associated with chronic graft-versus-host disease].
    Liu SW; Zhao YH; Ma J; Shen Z; Hu BH; Peng RM; Hong J
    Zhonghua Yan Ke Za Zhi; 2023 Oct; 59(10):805-813. PubMed ID: 37805414
    [No Abstract]   [Full Text] [Related]  

  • 13. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group.
    Sall K; Stevenson OD; Mundorf TK; Reis BL
    Ophthalmology; 2000 Apr; 107(4):631-9. PubMed ID: 10768324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Multicenter, Randomized, Double-Blind Evaluation of the Efficacy of TJO-087 Versus 0.05% Cyclosporine A in Moderate to Severe Dry Eye.
    Eom Y; Yoon KC; Kim HK; Song JS; Hyon JY; Kim HM
    J Ocul Pharmacol Ther; 2023; 39(1):27-35. PubMed ID: 36450107
    [No Abstract]   [Full Text] [Related]  

  • 15. Preoperative dry eyes disease in cataract patients with deficient tear break up time: evaluation of OSDI questionnaire, its subcategories and Keratograph 5M device results.
    Fydanaki O; Chalkiadaki E; Tsiogka A; Gartaganis PS; Karmiris E
    Int Ophthalmol; 2022 Oct; 42(10):3017-3025. PubMed ID: 35394587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effect of Ocular Demodex Colonization on Schirmer test and OSDI Scores in Newly Diagnosed Dry Eye Patients.
    Ayyildiz T; Sezgin FM
    Eye Contact Lens; 2020 Jan; 46 Suppl 1():S39-S41. PubMed ID: 31393313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dry Eye Treatment with Topical Cyclosporine 0.1% in Chondroitin Sulfate Ophthalmic Emulsion.
    Matossian C; Trattler W; Loh J
    Clin Ophthalmol; 2021; 15():1979-1984. PubMed ID: 34007151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of topical cyclosporine 0.1% in moderate-to-severe dry eye disease refractory to topical cyclosporine 0.05% regimen.
    Chan YH; Sun CC
    Taiwan J Ophthalmol; 2023; 13(1):68-74. PubMed ID: 37252163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of topical cyclosporine 0.05% and osmoprotective lubricating eye drops in treating dry eye disease and inflammation.
    Mullick R; Annavajjhala S; Thakur P; Mohapatra A; Shetty R; D'Souza S
    Indian J Ophthalmol; 2021 Dec; 69(12):3473-3477. PubMed ID: 34826977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of Preclinical Outcomes of a Topical Cationic Emulsion of Cyclosporine A for the Treatment of Ocular Surface Diseases.
    Daull P; Baudouin C; Liang H; Feraille L; Barabino S; Garrigue JS
    Ocul Immunol Inflamm; 2022; 30(7-8):1945-1955. PubMed ID: 34348575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.